News
Public · Published
TD Cowen maintains PTC Therapeutics at Buy, raises price target to $95 from $90
TD Cowen kept a Buy rating on PTC Therapeutics and raised its price target to $95 from $90, a 5.6% increase. The new target implies 58.4% upside from the Oct 30 close of $59.97.
Published:
Updated:
What happened
TD Cowen kept a Buy rating on PTC Therapeutics and raised its price target to $95 from $90, a 5.6% increase. The new target implies 58.4% upside from the Oct 30 close of $59.97.
Confirmed
Global impact / market context
A higher price target signals that this analyst expects the share price to rise more than previously thought. For a beginner, a price target is an analyst's estimate of where a stock could trade, not a guarantee, so it reflects opinion rather than a confirmed company result.
Analyst inference
Three recent analyst notes on PTC Therapeutics show price targets from $77 to $112, so views differ widely. TD Cowen's $95 sits in the middle of that range, suggesting moderate optimism rather than the most bullish or most cautious stance among those analysts.
Analyst inference
What to watch
- Watch whether other analysts change their price targets or ratings on PTC Therapeutics after TD Cowen's move, since the supplied notes range from $77 to $112. Confirmed
- Watch for future company updates on drug development or sales, because such updates could give analysts reason to change their price targets, though none are described in the article. Proposed
- Watch the gap between the $59.97 close and the $95 target, since a large implied upside suggests the analyst expects a big re-rating that may or may not occur. Analyst inference
Evidence
- Original source link unavailable